APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

Mucopolysaccharidosis Therapeutics

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Mucopolysaccharidosis Therapeutics Market Outlook and Growth Opportunities 2026

Report ID 17401476042 January 2026194 pages

Choose your research edition.

Industry ResearchMucopolysaccharidosis Therapeutics Industry Research Report 2026116 pages · $2,950 USDIndustry Growth & TrendsGlobal Mucopolysaccharidosis Therapeutics Industry Growth and Trends Forecast to 2032104 pages · $3,450 USDMarket StructureGlobal Mucopolysaccharidosis Therapeutics Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032195 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Mucopolysaccharidosis Therapeutics Market Outlook and Growth Opportunities 2026194 pages · $4,250 USDMarket Analysis & ForecastGlobal Mucopolysaccharidosis Therapeutics Market Analysis and Forecast 2026-2032198 pages · $4,950 USD

Market perspective

The global Mucopolysaccharidosis Therapeutics market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Mucopolysaccharidosis Therapeutics is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Mucopolysaccharidosis Therapeutics is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Mucopolysaccharidosis Therapeutics is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Mucopolysaccharidosis Therapeutics market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Mucopolysaccharidosis Therapeutics market include Abeona Therapeutics Inc., ArmaGen, BioMarin, Denali Therapeutics, Genzyme Corporation, Lysogene, REGENXBIO Inc., Sangamo Therapeutics and Shire (Takeda Pharmaceutical Company Limited), among others. In 2025, the top three vendors together accounted for approximately % of global market revenue.

This report provides an overview of the global Mucopolysaccharidosis Therapeutics market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Mucopolysaccharidosis Therapeutics and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Mucopolysaccharidosis Therapeutics revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global Mucopolysaccharidosis Therapeutics market.

Mucopolysaccharidosis Therapeutics Segment by Company

Abeona Therapeutics Inc.

ArmaGen

BioMarin

Denali Therapeutics

Genzyme Corporation

Lysogene

REGENXBIO Inc.

Sangamo Therapeutics

Shire (Takeda Pharmaceutical Company Limited)

Ultragenyx Pharmaceutical

Mucopolysaccharidosis Therapeutics Segment by Type

Intravenous

Intracerebroventricular (ICV)

Mucopolysaccharidosis Therapeutics Segment by Application

Hospital

Clinic

Other

Mucopolysaccharidosis Therapeutics Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global Mucopolysaccharidosis Therapeutics status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the Mucopolysaccharidosis Therapeutics key companies, revenue, market share, and recent developments.

3. To split the Mucopolysaccharidosis Therapeutics breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions Mucopolysaccharidosis Therapeutics market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Mucopolysaccharidosis Therapeutics significant trends, drivers, influence factors in global and regions.

6. To analyze Mucopolysaccharidosis Therapeutics competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Mucopolysaccharidosis Therapeutics market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Mucopolysaccharidosis Therapeutics and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Mucopolysaccharidosis Therapeutics.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Mucopolysaccharidosis Therapeutics industry.

Chapter 3: Detailed analysis of Mucopolysaccharidosis Therapeutics company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of Mucopolysaccharidosis Therapeutics in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of Mucopolysaccharidosis Therapeutics in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Mucopolysaccharidosis Therapeutics Industry Trends Table 2. Mucopolysaccharidosis Therapeutics Industry Drivers Table 3. Mucopolysaccharidosis Therapeutics Industry Opportunities and Challenges Table 4. Mucopolysaccharidosis Therapeutics Industry Restraints Table 5. Global Mucopolysaccharidosis Therapeutics Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Mucopolysaccharidosis Therapeutics Revenue Share by Company (2021-2026) Table 7. Global Mucopolysaccharidosis Therapeutics Company Ranking, (2024-2026) & (US$ Million) Table 8. Global Mucopolysaccharidosis Therapeutics Key Company Manufacturing Base & Headquarters Table 9. Global Mucopolysaccharidosis Therapeutics Company, Product Type & Application Table 10. Global Mucopolysaccharidosis Therapeutics Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global Mucopolysaccharidosis Therapeutics by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of Intravenous Table 15. Significant Companies of Intracerebroventricular (ICV) Table 16. Global Mucopolysaccharidosis Therapeutics Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 17. Global Mucopolysaccharidosis Therapeutics Sales Value by Type (2021-2026) & (US$ Million) Table 18. Global Mucopolysaccharidosis Therapeutics Sales Value by Type (2027-2032) & (US$ Million) Table 19. Global Mucopolysaccharidosis Therapeutics Sales Value Share by Type (2021-2026) Table 20. Global Mucopolysaccharidosis Therapeutics Sales Value Share by Type (2027-2032) Table 21. Significant Companies of Hospital Table 22. Significant Companies of Clinic Table 23. Significant Companies of Other Table 24. Global Mucopolysaccharidosis Therapeutics Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 25. Global Mucopolysaccharidosis Therapeutics Sales Value by Application (2021-2026) & (US$ Million) Table 26. Global Mucopolysaccharidosis Therapeutics Sales Value by Application (2027-2032) & (US$ Million) Table 27. Global Mucopolysaccharidosis Therapeutics Sales Value Share by Application (2021-2026) Table 28. Global Mucopolysaccharidosis Therapeutics Sales Value Share by Application (2027-2032) Table 29. Global Mucopolysaccharidosis Therapeutics Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 30. Global Mucopolysaccharidosis Therapeutics Sales Value by Region (2021-2026) & (US$ Million) Table 31. Global Mucopolysaccharidosis Therapeutics Sales Value Share by Region (2021-2026) Table 32. Global Mucopolysaccharidosis Therapeutics Sales Value by Region (2027-2032) & (US$ Million) Table 33. Global Mucopolysaccharidosis Therapeutics Sales Value Share by Region (2027-2032) Table 34. Global Mucopolysaccharidosis Therapeutics Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 35. Global Mucopolysaccharidosis Therapeutics Sales Value by Country (2021-2026) & (US$ Million) Table 36. Global Mucopolysaccharidosis Therapeutics Sales Value Market Share by Country (2021-2026) Table 37. Global Mucopolysaccharidosis Therapeutics Sales Value by Country (2027-2032) & (US$ Million) Table 38. Global Mucopolysaccharidosis Therapeutics Sales Value Market Share by Country (2027-2032) Table 39. Abeona Therapeutics Inc. Company Information Table 40. Abeona Therapeutics Inc. Business Overview Table 41. Abeona Therapeutics Inc. Mucopolysaccharidosis Therapeutics Revenue (US$ Million) and Gross Margin (2021-2026) Table 42. Abeona Therapeutics Inc. Mucopolysaccharidosis Therapeutics Product Portfolio Table 43. Abeona Therapeutics Inc. Recent Development Table 44. ArmaGen Company Information Table 45. ArmaGen Business Overview Table 46. ArmaGen Mucopolysaccharidosis Therapeutics Revenue (US$ Million) and Gross Margin (2021-2026) Table 47. ArmaGen Mucopolysaccharidosis Therapeutics Product Portfolio Table 48. ArmaGen Recent Development Table 49. BioMarin Company Information Table 50. BioMarin Business Overview Table 51. BioMarin Mucopolysaccharidosis Therapeutics Revenue (US$ Million) and Gross Margin (2021-2026) Table 52. BioMarin Mucopolysaccharidosis Therapeutics Product Portfolio Table 53. BioMarin Recent Development Table 54. Denali Therapeutics Company Information Table 55. Denali Therapeutics Business Overview Table 56. Denali Therapeutics Mucopolysaccharidosis Therapeutics Revenue (US$ Million) and Gross Margin (2021-2026) Table 57. Denali Therapeutics Mucopolysaccharidosis Therapeutics Product Portfolio Table 58. Denali Therapeutics Recent Development Table 59. Genzyme Corporation Company Information Table 60. Genzyme Corporation Business Overview Table 61. Genzyme Corporation Mucopolysaccharidosis Therapeutics Revenue (US$ Million) and Gross Margin (2021-2026) Table 62. Genzyme Corporation Mucopolysaccharidosis Therapeutics Product Portfolio Table 63. Genzyme Corporation Recent Development Table 64. Lysogene Company Information Table 65. Lysogene Business Overview Table 66. Lysogene Mucopolysaccharidosis Therapeutics Revenue (US$ Million) and Gross Margin (2021-2026) Table 67. Lysogene Mucopolysaccharidosis Therapeutics Product Portfolio Table 68. Lysogene Recent Development Table 69. REGENXBIO Inc. Company Information Table 70. REGENXBIO Inc. Business Overview Table 71. REGENXBIO Inc. Mucopolysaccharidosis Therapeutics Revenue (US$ Million) and Gross Margin (2021-2026) Table 72. REGENXBIO Inc. Mucopolysaccharidosis Therapeutics Product Portfolio Table 73. REGENXBIO Inc. Recent Development Table 74. Sangamo Therapeutics Company Information Table 75. Sangamo Therapeutics Business Overview Table 76. Sangamo Therapeutics Mucopolysaccharidosis Therapeutics Revenue (US$ Million) and Gross Margin (2021-2026) Table 77. Sangamo Therapeutics Mucopolysaccharidosis Therapeutics Product Portfolio Table 78. Sangamo Therapeutics Recent Development Table 79. Shire (Takeda Pharmaceutical Company Limited) Company Information Table 80. Shire (Takeda Pharmaceutical Company Limited) Business Overview Table 81. Shire (Takeda Pharmaceutical Company Limited) Mucopolysaccharidosis Therapeutics Revenue (US$ Million) and Gross Margin (2021-2026) Table 82. Shire (Takeda Pharmaceutical Company Limited) Mucopolysaccharidosis Therapeutics Product Portfolio Table 83. Shire (Takeda Pharmaceutical Company Limited) Recent Development Table 84. Ultragenyx Pharmaceutical Company Information Table 85. Ultragenyx Pharmaceutical Business Overview Table 86. Ultragenyx Pharmaceutical Mucopolysaccharidosis Therapeutics Revenue (US$ Million) and Gross Margin (2021-2026) Table 87. Ultragenyx Pharmaceutical Mucopolysaccharidosis Therapeutics Product Portfolio Table 88. Ultragenyx Pharmaceutical Recent Development Table 89. Research Programs/Design for This Report Table 90. Authors List of This Report Table 91. Secondary Sources Table 92. Primary Sources List of Figures Figure 1. Mucopolysaccharidosis Therapeutics Product Image Figure 2. Global Mucopolysaccharidosis Therapeutics Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Mucopolysaccharidosis Therapeutics Market Size (2021-2032) & (US$ Million) Figure 4. Global Mucopolysaccharidosis Therapeutics Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. Intravenous Image Figure 8. Intracerebroventricular (ICV) Image Figure 9. Global Mucopolysaccharidosis Therapeutics Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 10. Global Mucopolysaccharidosis Therapeutics Sales Value Share 2021 VS 2025 VS 2032 Figure 11. Global Mucopolysaccharidosis Therapeutics Sales Value Share by Type (2021-2032) Figure 12. Hospital Image Figure 13. Clinic Image Figure 14. Other Image Figure 15. Global Mucopolysaccharidosis Therapeutics Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 16. Global Mucopolysaccharidosis Therapeutics Sales Value Share 2021 VS 2025 VS 2032 Figure 17. Global Mucopolysaccharidosis Therapeutics Sales Value Share by Application (2021-2032) Figure 18. Global Mucopolysaccharidosis Therapeutics Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 19. Global Mucopolysaccharidosis Therapeutics Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 20. North America Mucopolysaccharidosis Therapeutics Sales Value (2021-2032) & (US$ Million) Figure 21. North America Mucopolysaccharidosis Therapeutics Sales Value Share by Country (%), 2025 VS 2032 Figure 22. Europe Mucopolysaccharidosis Therapeutics Sales Value (2021-2032) & (US$ Million) Figure 23. Europe Mucopolysaccharidosis Therapeutics Sales Value Share by Country (%), 2025 VS 2032 Figure 24. Asia-Pacific Mucopolysaccharidosis Therapeutics Sales Value (2021-2032) & (US$ Million) Figure 25. Asia-Pacific Mucopolysaccharidosis Therapeutics Sales Value Share by Country (%), 2025 VS 2032 Figure 26. South America Mucopolysaccharidosis Therapeutics Sales Value (2021-2032) & (US$ Million) Figure 27. South America Mucopolysaccharidosis Therapeutics Sales Value Share by Country (%), 2025 VS 2032 Figure 28. Middle East & Africa Mucopolysaccharidosis Therapeutics Sales Value (2021-2032) & (US$ Million) Figure 29. Middle East & Africa Mucopolysaccharidosis Therapeutics Sales Value Share by Country (%), 2025 VS 2032 Figure 30. USA Mucopolysaccharidosis Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 31. USA Mucopolysaccharidosis Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 32. USA Mucopolysaccharidosis Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 33. Canada Mucopolysaccharidosis Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 34. Canada Mucopolysaccharidosis Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 35. Canada Mucopolysaccharidosis Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 36. Mexico Mucopolysaccharidosis Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 37. Mexico Mucopolysaccharidosis Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 38. Mexico Mucopolysaccharidosis Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 39. Germany Mucopolysaccharidosis Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 40. Germany Mucopolysaccharidosis Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 41. Germany Mucopolysaccharidosis Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 42. France Mucopolysaccharidosis Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 43. France Mucopolysaccharidosis Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 44. France Mucopolysaccharidosis Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 45. U.K. Mucopolysaccharidosis Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 46. U.K. Mucopolysaccharidosis Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 47. U.K. Mucopolysaccharidosis Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 48. Italy Mucopolysaccharidosis Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 49. Italy Mucopolysaccharidosis Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 50. Italy Mucopolysaccharidosis Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 51. Spain Mucopolysaccharidosis Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 52. Spain Mucopolysaccharidosis Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 53. Spain Mucopolysaccharidosis Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 54. Russia Mucopolysaccharidosis Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 55. Russia Mucopolysaccharidosis Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 56. Russia Mucopolysaccharidosis Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 57. Netherlands Mucopolysaccharidosis Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 58. Netherlands Mucopolysaccharidosis Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 59. Netherlands Mucopolysaccharidosis Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 60. Nordic Countries Mucopolysaccharidosis Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 61. Nordic Countries Mucopolysaccharidosis Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 62. Nordic Countries Mucopolysaccharidosis Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 63. China Mucopolysaccharidosis Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 64. China Mucopolysaccharidosis Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 65. China Mucopolysaccharidosis Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 66. Japan Mucopolysaccharidosis Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 67. Japan Mucopolysaccharidosis Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 68. Japan Mucopolysaccharidosis Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 69. South Korea Mucopolysaccharidosis Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 70. South Korea Mucopolysaccharidosis Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 71. South Korea Mucopolysaccharidosis Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 72. India Mucopolysaccharidosis Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 73. India Mucopolysaccharidosis Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 74. India Mucopolysaccharidosis Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 75. Australia Mucopolysaccharidosis Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 76. Australia Mucopolysaccharidosis Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 77. Australia Mucopolysaccharidosis Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 78. Southeast Asia Mucopolysaccharidosis Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 79. Southeast Asia Mucopolysaccharidosis Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 80. Southeast Asia Mucopolysaccharidosis Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 81. Brazil Mucopolysaccharidosis Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 82. Brazil Mucopolysaccharidosis Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 83. Brazil Mucopolysaccharidosis Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 84. Argentina Mucopolysaccharidosis Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 85. Argentina Mucopolysaccharidosis Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 86. Argentina Mucopolysaccharidosis Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 87. Chile Mucopolysaccharidosis Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 88. Chile Mucopolysaccharidosis Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 89. Chile Mucopolysaccharidosis Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 90. Colombia Mucopolysaccharidosis Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 91. Colombia Mucopolysaccharidosis Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 92. Colombia Mucopolysaccharidosis Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 93. Peru Mucopolysaccharidosis Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 94. Peru Mucopolysaccharidosis Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 95. Peru Mucopolysaccharidosis Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 96. Saudi Arabia Mucopolysaccharidosis Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 97. Saudi Arabia Mucopolysaccharidosis Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 98. Saudi Arabia Mucopolysaccharidosis Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 99. Israel Mucopolysaccharidosis Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 100. Israel Mucopolysaccharidosis Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 101. Israel Mucopolysaccharidosis Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 102. UAE Mucopolysaccharidosis Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 103. UAE Mucopolysaccharidosis Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 104. UAE Mucopolysaccharidosis Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 105. Turkey Mucopolysaccharidosis Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 106. Turkey Mucopolysaccharidosis Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 107. Turkey Mucopolysaccharidosis Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 108. Iran Mucopolysaccharidosis Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 109. Iran Mucopolysaccharidosis Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 110. Iran Mucopolysaccharidosis Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 111. Egypt Mucopolysaccharidosis Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 112. Egypt Mucopolysaccharidosis Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 113. Egypt Mucopolysaccharidosis Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 114. Years Considered Figure 115. Research Process Figure 116. Key Executives Interviewed

Scope & coverage.

Types
  • Intravenous
  • Intracerebroventricular (ICV)
Applications
  • Hospital
  • Clinic
  • Other
Companies covered
  • Abeona Therapeutics Inc.
  • ArmaGen
  • BioMarin
  • Denali Therapeutics
  • Genzyme Corporation
  • Lysogene
  • REGENXBIO Inc.
  • Sangamo Therapeutics
  • Shire (Takeda Pharmaceutical Company Limited)
  • Ultragenyx Pharmaceutical

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Mucopolysaccharidosis Therapeutics Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Mucopolysaccharidosis Therapeutics Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 Mucopolysaccharidosis Therapeutics Market Dynamics
  1. 2.1 Mucopolysaccharidosis Therapeutics Industry Trends
  2. 2.2 Mucopolysaccharidosis Therapeutics Industry Drivers
  3. 2.3 Mucopolysaccharidosis Therapeutics Industry Opportunities and Challenges
  4. 2.4 Mucopolysaccharidosis Therapeutics Industry Restraints
3 Mucopolysaccharidosis Therapeutics Market by Company
  1. 3.1 Global Mucopolysaccharidosis Therapeutics Company Revenue Ranking in 2025
  2. 3.2 Global Mucopolysaccharidosis Therapeutics Revenue by Company (2021-2026)
  3. 3.3 Global Mucopolysaccharidosis Therapeutics Company Ranking (2024-2026)
  4. 3.4 Global Mucopolysaccharidosis Therapeutics Company Manufacturing Base and Headquarters
  5. 3.5 Global Mucopolysaccharidosis Therapeutics Company Product Type and Application
  6. 3.6 Global Mucopolysaccharidosis Therapeutics Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global Mucopolysaccharidosis Therapeutics Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 Mucopolysaccharidosis Therapeutics Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 Mucopolysaccharidosis Therapeutics Market by Type
  1. 4.1 Mucopolysaccharidosis Therapeutics Type Introduction
  2. 4.1.1 Intravenous
  3. 4.1.2 Intracerebroventricular (ICV)
  4. 4.2 Global Mucopolysaccharidosis Therapeutics Sales Value by Type
  5. 4.2.1 Global Mucopolysaccharidosis Therapeutics Sales Value by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global Mucopolysaccharidosis Therapeutics Sales Value by Type (2021-2032)
  7. 4.2.3 Global Mucopolysaccharidosis Therapeutics Sales Value Share by Type (2021-2032)
5 Mucopolysaccharidosis Therapeutics Market by Application
  1. 5.1 Mucopolysaccharidosis Therapeutics Application Introduction
  2. 5.1.1 Hospital
  3. 5.1.2 Clinic
  4. 5.1.3 Other
  5. 5.2 Global Mucopolysaccharidosis Therapeutics Sales Value by Application
  6. 5.2.1 Global Mucopolysaccharidosis Therapeutics Sales Value by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Mucopolysaccharidosis Therapeutics Sales Value by Application (2021-2032)
  8. 5.2.3 Global Mucopolysaccharidosis Therapeutics Sales Value Share by Application (2021-2032)
6 Mucopolysaccharidosis Therapeutics Regional Value Analysis
  1. 6.1 Global Mucopolysaccharidosis Therapeutics Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Mucopolysaccharidosis Therapeutics Sales Value by Region (2021-2032)
  3. 6.2.1 Global Mucopolysaccharidosis Therapeutics Sales Value by Region: 2021-2026
  4. 6.2.2 Global Mucopolysaccharidosis Therapeutics Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Mucopolysaccharidosis Therapeutics Sales Value (2021-2032)
  7. 6.3.2 North America Mucopolysaccharidosis Therapeutics Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe Mucopolysaccharidosis Therapeutics Sales Value (2021-2032)
  10. 6.4.2 Europe Mucopolysaccharidosis Therapeutics Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific Mucopolysaccharidosis Therapeutics Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific Mucopolysaccharidosis Therapeutics Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America Mucopolysaccharidosis Therapeutics Sales Value (2021-2032)
  16. 6.6.2 South America Mucopolysaccharidosis Therapeutics Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa Mucopolysaccharidosis Therapeutics Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa Mucopolysaccharidosis Therapeutics Sales Value Share by Country, 2025 VS 2032
7 Mucopolysaccharidosis Therapeutics Country-level Value Analysis
  1. 7.1 Global Mucopolysaccharidosis Therapeutics Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Mucopolysaccharidosis Therapeutics Sales Value by Country (2021-2032)
  3. 7.2.1 Global Mucopolysaccharidosis Therapeutics Sales Value by Country (2021-2026)
  4. 7.2.2 Global Mucopolysaccharidosis Therapeutics Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA Mucopolysaccharidosis Therapeutics Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA Mucopolysaccharidosis Therapeutics Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA Mucopolysaccharidosis Therapeutics Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada Mucopolysaccharidosis Therapeutics Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada Mucopolysaccharidosis Therapeutics Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada Mucopolysaccharidosis Therapeutics Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico Mucopolysaccharidosis Therapeutics Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico Mucopolysaccharidosis Therapeutics Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico Mucopolysaccharidosis Therapeutics Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany Mucopolysaccharidosis Therapeutics Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany Mucopolysaccharidosis Therapeutics Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany Mucopolysaccharidosis Therapeutics Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France Mucopolysaccharidosis Therapeutics Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France Mucopolysaccharidosis Therapeutics Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France Mucopolysaccharidosis Therapeutics Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. Mucopolysaccharidosis Therapeutics Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. Mucopolysaccharidosis Therapeutics Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. Mucopolysaccharidosis Therapeutics Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy Mucopolysaccharidosis Therapeutics Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy Mucopolysaccharidosis Therapeutics Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy Mucopolysaccharidosis Therapeutics Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain Mucopolysaccharidosis Therapeutics Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain Mucopolysaccharidosis Therapeutics Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain Mucopolysaccharidosis Therapeutics Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia Mucopolysaccharidosis Therapeutics Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia Mucopolysaccharidosis Therapeutics Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia Mucopolysaccharidosis Therapeutics Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands Mucopolysaccharidosis Therapeutics Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands Mucopolysaccharidosis Therapeutics Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands Mucopolysaccharidosis Therapeutics Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries Mucopolysaccharidosis Therapeutics Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries Mucopolysaccharidosis Therapeutics Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries Mucopolysaccharidosis Therapeutics Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China Mucopolysaccharidosis Therapeutics Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China Mucopolysaccharidosis Therapeutics Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China Mucopolysaccharidosis Therapeutics Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan Mucopolysaccharidosis Therapeutics Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan Mucopolysaccharidosis Therapeutics Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan Mucopolysaccharidosis Therapeutics Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea Mucopolysaccharidosis Therapeutics Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea Mucopolysaccharidosis Therapeutics Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea Mucopolysaccharidosis Therapeutics Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India Mucopolysaccharidosis Therapeutics Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India Mucopolysaccharidosis Therapeutics Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India Mucopolysaccharidosis Therapeutics Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia Mucopolysaccharidosis Therapeutics Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia Mucopolysaccharidosis Therapeutics Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia Mucopolysaccharidosis Therapeutics Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia Mucopolysaccharidosis Therapeutics Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia Mucopolysaccharidosis Therapeutics Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia Mucopolysaccharidosis Therapeutics Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil Mucopolysaccharidosis Therapeutics Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil Mucopolysaccharidosis Therapeutics Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil Mucopolysaccharidosis Therapeutics Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina Mucopolysaccharidosis Therapeutics Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina Mucopolysaccharidosis Therapeutics Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina Mucopolysaccharidosis Therapeutics Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile Mucopolysaccharidosis Therapeutics Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile Mucopolysaccharidosis Therapeutics Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile Mucopolysaccharidosis Therapeutics Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia Mucopolysaccharidosis Therapeutics Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia Mucopolysaccharidosis Therapeutics Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia Mucopolysaccharidosis Therapeutics Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru Mucopolysaccharidosis Therapeutics Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru Mucopolysaccharidosis Therapeutics Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru Mucopolysaccharidosis Therapeutics Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia Mucopolysaccharidosis Therapeutics Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia Mucopolysaccharidosis Therapeutics Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia Mucopolysaccharidosis Therapeutics Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel Mucopolysaccharidosis Therapeutics Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel Mucopolysaccharidosis Therapeutics Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel Mucopolysaccharidosis Therapeutics Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE Mucopolysaccharidosis Therapeutics Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE Mucopolysaccharidosis Therapeutics Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE Mucopolysaccharidosis Therapeutics Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey Mucopolysaccharidosis Therapeutics Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey Mucopolysaccharidosis Therapeutics Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey Mucopolysaccharidosis Therapeutics Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran Mucopolysaccharidosis Therapeutics Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran Mucopolysaccharidosis Therapeutics Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran Mucopolysaccharidosis Therapeutics Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt Mucopolysaccharidosis Therapeutics Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt Mucopolysaccharidosis Therapeutics Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt Mucopolysaccharidosis Therapeutics Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Abeona Therapeutics Inc.
  2. 8.1.1 Abeona Therapeutics Inc. Company Information
  3. 8.1.2 Abeona Therapeutics Inc. Business Overview
  4. 8.1.3 Abeona Therapeutics Inc. Mucopolysaccharidosis Therapeutics Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Abeona Therapeutics Inc. Mucopolysaccharidosis Therapeutics Product Portfolio
  6. 8.1.5 Abeona Therapeutics Inc. Recent Developments
  7. 8.2 ArmaGen
  8. 8.2.1 ArmaGen Company Information
  9. 8.2.2 ArmaGen Business Overview
  10. 8.2.3 ArmaGen Mucopolysaccharidosis Therapeutics Revenue and Gross Margin (2021-2026)
  11. 8.2.4 ArmaGen Mucopolysaccharidosis Therapeutics Product Portfolio
  12. 8.2.5 ArmaGen Recent Developments
  13. 8.3 BioMarin
  14. 8.3.1 BioMarin Company Information
  15. 8.3.2 BioMarin Business Overview
  16. 8.3.3 BioMarin Mucopolysaccharidosis Therapeutics Revenue and Gross Margin (2021-2026)
  17. 8.3.4 BioMarin Mucopolysaccharidosis Therapeutics Product Portfolio
  18. 8.3.5 BioMarin Recent Developments
  19. 8.4 Denali Therapeutics
  20. 8.4.1 Denali Therapeutics Company Information
  21. 8.4.2 Denali Therapeutics Business Overview
  22. 8.4.3 Denali Therapeutics Mucopolysaccharidosis Therapeutics Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Denali Therapeutics Mucopolysaccharidosis Therapeutics Product Portfolio
  24. 8.4.5 Denali Therapeutics Recent Developments
  25. 8.5 Genzyme Corporation
  26. 8.5.1 Genzyme Corporation Company Information
  27. 8.5.2 Genzyme Corporation Business Overview
  28. 8.5.3 Genzyme Corporation Mucopolysaccharidosis Therapeutics Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Genzyme Corporation Mucopolysaccharidosis Therapeutics Product Portfolio
  30. 8.5.5 Genzyme Corporation Recent Developments
  31. 8.6 Lysogene
  32. 8.6.1 Lysogene Company Information
  33. 8.6.2 Lysogene Business Overview
  34. 8.6.3 Lysogene Mucopolysaccharidosis Therapeutics Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Lysogene Mucopolysaccharidosis Therapeutics Product Portfolio
  36. 8.6.5 Lysogene Recent Developments
  37. 8.7 REGENXBIO Inc.
  38. 8.7.1 REGENXBIO Inc. Company Information
  39. 8.7.2 REGENXBIO Inc. Business Overview
  40. 8.7.3 REGENXBIO Inc. Mucopolysaccharidosis Therapeutics Revenue and Gross Margin (2021-2026)
  41. 8.7.4 REGENXBIO Inc. Mucopolysaccharidosis Therapeutics Product Portfolio
  42. 8.7.5 REGENXBIO Inc. Recent Developments
  43. 8.8 Sangamo Therapeutics
  44. 8.8.1 Sangamo Therapeutics Company Information
  45. 8.8.2 Sangamo Therapeutics Business Overview
  46. 8.8.3 Sangamo Therapeutics Mucopolysaccharidosis Therapeutics Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Sangamo Therapeutics Mucopolysaccharidosis Therapeutics Product Portfolio
  48. 8.8.5 Sangamo Therapeutics Recent Developments
  49. 8.9 Shire (Takeda Pharmaceutical Company Limited)
  50. 8.9.1 Shire (Takeda Pharmaceutical Company Limited) Company Information
  51. 8.9.2 Shire (Takeda Pharmaceutical Company Limited) Business Overview
  52. 8.9.3 Shire (Takeda Pharmaceutical Company Limited) Mucopolysaccharidosis Therapeutics Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Shire (Takeda Pharmaceutical Company Limited) Mucopolysaccharidosis Therapeutics Product Portfolio
  54. 8.9.5 Shire (Takeda Pharmaceutical Company Limited) Recent Developments
  55. 8.10 Ultragenyx Pharmaceutical
  56. 8.10.1 Ultragenyx Pharmaceutical Company Information
  57. 8.10.2 Ultragenyx Pharmaceutical Business Overview
  58. 8.10.3 Ultragenyx Pharmaceutical Mucopolysaccharidosis Therapeutics Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Ultragenyx Pharmaceutical Mucopolysaccharidosis Therapeutics Product Portfolio
  60. 8.10.5 Ultragenyx Pharmaceutical Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst